Showing results (271-280 of 308) with videos related to

Sort By:
Pageof 31
Materials (Basel, Switzerland)|October 27, 2022
Effects of Severe Plastic Deformation and Ultrasonic Treatment on the Structure, Strength, and Corrosion Resistance of Mg-Al-Zn AlloyDenis A Aksenov, Ayrat A Nazarov, Georgiy I Raab, et al.
The American Journal of Pathology|September 17, 1999
Isolation of mouse stromal cells associated with a human tumor using differential diphtheria toxin sensitivityJ L Arbiser, G Raab, R M Rohan, et al.
Critical Care Medicine|October 15, 2025
Five Years After Extracorporeal Membrane Oxygenation: A Prospective Cohort Study of Health-Related Quality of Life and Patient OutcomesFloris E J Jolink, Marisa Onrust, Dinis Dos Reis Miranda, et al.
Prostate Cancer and Prostatic Diseases|March 22, 2021
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world populationH M Westgeest, M C P Kuppen, A J M van den Eertwegh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991Michel Bolla, Philippe Maingon, Christian Carrie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2021
Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk DiseaseMichel Bolla, Anouk Neven, Philippe Maingon, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 10, 2026
Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registryK J M van der Velden, D Bosch, Z Vassilev, et al.
Seminars in Oncology|July 30, 1999
The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancerS D Costa, G von Minckwitz, G Raab, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 28, 2003
Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS studyPaul Verboom, Harm van Tinteren, Otto S Hoekstra, et al.
Pageof 31